Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

January 26, 2017

An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay, head of Informa Pharma Intelligence Products, shares with Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, his thoughts on how shareholder pressure for genuine patient benefits has implications for the pharma and biotech industries.

 

 


Meet Covance at BIO-Europe Spring® taking place in Barcelona, Spain, March 20–22, 2017. Find out how you can be a part of our event

Previous Article
Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017
Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporter...

Next Article
Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?
Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical ...